News

New Research on Probiotics Shows Promise for Fighting Obesity

According to a new study published by George Mason University  researchers Dr. Robin Couch and Dr. Allyson Dailey, in collaboration with researchers at the  U.S. Department of Agriculture (USDA), showed probiotics may play a pivotal role in preventive  medicine.

High fat diets are a leading cause of obesity and can trigger the onset of metabolic syndrome.  The research team found that probiotic intervention has significant potential for addressing  obesity-related diseases.

The study examined the impact of a high fat diet in pigs. Organ tissue samples revealed that  probiotic supplementation countered many of the adverse consequences of a high fat diet  based on metabolite levels.

“Not only did we discover that the kidneys and brain are extremely sensitive to diets higher in  fat, but we also observed that probiotic supplementation reverted metabolite levels of pigs fed a  high fat diet to levels seen in pigs given a nutritionally balanced diet,” said Dr. Dailey.

Dr. Couch and Dr. Dailey worked with USDA researchers Dr. Gloria Solano-Aguilar, DVM, and  Dr. Joseph F. Urban on the study, which was published by Metabolites in February.

While only one probiotic strain was tested, Lacticaseibacillus paracasei (Chr. Hansen,  Denmark), the research team intends to explore the effects of other strains in the future.

“We’d like to see if certain probiotic strains are more advantageous for inducing changes in host  metabolic responses after consumption of high fat diet,” said Dr. Couch.

“Although more research is required before probiotic supplementation can be recommended as  part of one’s everyday routine, this study shows the effect it has on organ metabolite  composition,” said Dr. Couch. “The metabolome influence on the body is a blossoming field of study, and our results are further evidence that probiotics could contribute to normalize affected  metabolites, especially for those affected after consumption of a higher fat diet.”

Traditionally, probiotic research involves inspecting the gastrointestinal tract composition, such  as analyzing fecal microbiome composition or looking for inflammatory markers in blood  samples. By using organ tissue samples, researchers can directly measure the impact of  probiotics on metabolites in the body.

“This study shows that tissue derived metabolites can be modulated by dietary interventions.  However, additional research is needed to see if changes in these markers found in organs after

feeding probiotics could be followed in human samples of serum, urine or saliva,” said Dr.  Solano-Aguilar.

For more information, contact John Hollis at 571-396-1578 or jhollis2@gmu.edu

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation